RU2006144863A - Модуляторы андрогеновых рецепторов и способ лечения заболеваний с их помощью - Google Patents

Модуляторы андрогеновых рецепторов и способ лечения заболеваний с их помощью Download PDF

Info

Publication number
RU2006144863A
RU2006144863A RU2006144863/04A RU2006144863A RU2006144863A RU 2006144863 A RU2006144863 A RU 2006144863A RU 2006144863/04 A RU2006144863/04 A RU 2006144863/04A RU 2006144863 A RU2006144863 A RU 2006144863A RU 2006144863 A RU2006144863 A RU 2006144863A
Authority
RU
Russia
Prior art keywords
azabicyclo
oct
cyanonaphthalen
endo
carbonitrile
Prior art date
Application number
RU2006144863/04A
Other languages
English (en)
Inventor
Натали ШЛИНГЕР (DK)
Натали ШЛИНГЕР
Ян ПАВЛАС (DK)
Ян ПАВЛАС
Алма ФЕЙЗИЧ (DK)
Алма ФЕЙЗИЧ
Роджер ОЛССОН (SE)
Роджер ОЛССОН
Бригитте Винтер ЛУНД (DK)
Бригитте Винтер ЛУНД
Фабрицио БАДАЛАССИ (DK)
Фабрицио БАДАЛАССИ
Расмус ЛЕВИНСКИ (DK)
Расмус ЛЕВИНСКИ
Миккель Боас ТЮГЕСЕН (DK)
Миккель Боас ТЮГЕСЕН
Original Assignee
Акэдиа Фармасьютикалз Инк. (Us)
Акэдиа Фармасьютикалз Инк.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Акэдиа Фармасьютикалз Инк. (Us), Акэдиа Фармасьютикалз Инк. filed Critical Акэдиа Фармасьютикалз Инк. (Us)
Publication of RU2006144863A publication Critical patent/RU2006144863A/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D207/08—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon radicals, substituted by hetero atoms, attached to ring carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/12—Drugs for genital or sexual disorders; Contraceptives for climacteric disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/02—Nutrients, e.g. vitamins, minerals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/26—Androgens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/30—Oestrogens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C255/00—Carboxylic acid nitriles
    • C07C255/49—Carboxylic acid nitriles having cyano groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton
    • C07C255/58—Carboxylic acid nitriles having cyano groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton containing cyano groups and singly-bound nitrogen atoms, not being further bound to other hetero atoms, bound to the carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D207/08—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon radicals, substituted by hetero atoms, attached to ring carbon atoms
    • C07D207/09—Radicals substituted by nitrogen atoms, not forming part of a nitro radical
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D207/10—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D207/10—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D207/12—Oxygen or sulfur atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D207/10—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D207/14—Nitrogen atoms not forming part of a nitro radical
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D207/10—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D207/16—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/18—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member
    • C07D207/20—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
    • C07D211/18—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D211/20—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by singly bound oxygen or sulphur atoms
    • C07D211/22—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by singly bound oxygen or sulphur atoms by oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
    • C07D211/18—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D211/30—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by doubly bound oxygen or sulfur atoms or by two oxygen or sulfur atoms singly bound to the same carbon atom
    • C07D211/32—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by doubly bound oxygen or sulfur atoms or by two oxygen or sulfur atoms singly bound to the same carbon atom by oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
    • C07D211/18—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D211/34—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D211/38—Halogen atoms or nitro radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D211/40—Oxygen atoms
    • C07D211/42—Oxygen atoms attached in position 3 or 5
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D211/40—Oxygen atoms
    • C07D211/44—Oxygen atoms attached in position 4
    • C07D211/46—Oxygen atoms attached in position 4 having a hydrogen atom as the second substituent in position 4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D211/40—Oxygen atoms
    • C07D211/44—Oxygen atoms attached in position 4
    • C07D211/48—Oxygen atoms attached in position 4 having an acyclic carbon atom attached in position 4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D211/56—Nitrogen atoms
    • C07D211/58—Nitrogen atoms attached in position 4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D211/60—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D211/60—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D211/62—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals attached in position 4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D211/60—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D211/62—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals attached in position 4
    • C07D211/64—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals attached in position 4 having an aryl radical as the second substituent in position 4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/68—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member
    • C07D211/70—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/20—Oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/38—Nitrogen atoms
    • C07D215/40—Nitrogen atoms attached in position 8
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/48—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
    • C07D217/02—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with only hydrogen atoms or radicals containing only carbon and hydrogen atoms, directly attached to carbon atoms of the nitrogen-containing ring; Alkylene-bis-isoquinolines
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
    • C07D217/02—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with only hydrogen atoms or radicals containing only carbon and hydrogen atoms, directly attached to carbon atoms of the nitrogen-containing ring; Alkylene-bis-isoquinolines
    • C07D217/04—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with only hydrogen atoms or radicals containing only carbon and hydrogen atoms, directly attached to carbon atoms of the nitrogen-containing ring; Alkylene-bis-isoquinolines with hydrocarbon or substituted hydrocarbon radicals attached to the ring nitrogen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
    • C07D217/22—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the nitrogen-containing ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
    • C07D217/22—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the nitrogen-containing ring
    • C07D217/24—Oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D221/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00
    • C07D221/02—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00 condensed with carbocyclic rings or ring systems
    • C07D221/20—Spiro-condensed ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D221/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00
    • C07D221/02—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00 condensed with carbocyclic rings or ring systems
    • C07D221/22—Bridged ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D237/00—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings
    • C07D237/26—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings condensed with carbocyclic rings or ring systems
    • C07D237/30—Phthalazines
    • C07D237/34—Phthalazines with nitrogen atoms directly attached to carbon atoms of the nitrogen-containing ring, e.g. hydrazine radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
    • C07D241/36—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings condensed with carbocyclic rings or ring systems
    • C07D241/38—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings condensed with carbocyclic rings or ring systems with only hydrogen or carbon atoms directly attached to the ring nitrogen atoms
    • C07D241/40—Benzopyrazines
    • C07D241/42—Benzopyrazines with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to carbon atoms of the hetero ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D285/00—Heterocyclic compounds containing rings having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by groups C07D275/00 - C07D283/00
    • C07D285/01—Five-membered rings
    • C07D285/02—Thiadiazoles; Hydrogenated thiadiazoles
    • C07D285/14—Thiadiazoles; Hydrogenated thiadiazoles condensed with carbocyclic rings or ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
    • C07D295/06—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by halogen atoms or nitro radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
    • C07D295/06—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by halogen atoms or nitro radicals
    • C07D295/073—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by halogen atoms or nitro radicals with the ring nitrogen atoms and the substituents separated by carbocyclic rings or by carbon chains interrupted by carbocyclic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
    • C07D295/08—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms
    • C07D295/096—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms with the ring nitrogen atoms and the oxygen or sulfur atoms separated by carbocyclic rings or by carbon chains interrupted by carbocyclic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
    • C07D295/14—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D295/155—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals with the ring nitrogen atoms and the carbon atoms with three bonds to hetero atoms separated by carbocyclic rings or by carbon chains interrupted by carbocyclic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D451/00—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D451/00—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof
    • C07D451/02—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof containing not further condensed 8-azabicyclo [3.2.1] octane or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane; Cyclic acetals thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D451/00—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof
    • C07D451/02—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof containing not further condensed 8-azabicyclo [3.2.1] octane or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane; Cyclic acetals thereof
    • C07D451/04—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof containing not further condensed 8-azabicyclo [3.2.1] octane or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane; Cyclic acetals thereof with hetero atoms directly attached in position 3 of the 8-azabicyclo [3.2.1] octane or in position 7 of the 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D451/00—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof
    • C07D451/02—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof containing not further condensed 8-azabicyclo [3.2.1] octane or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane; Cyclic acetals thereof
    • C07D451/04—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof containing not further condensed 8-azabicyclo [3.2.1] octane or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane; Cyclic acetals thereof with hetero atoms directly attached in position 3 of the 8-azabicyclo [3.2.1] octane or in position 7 of the 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring system
    • C07D451/06—Oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/08—Bridged systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/10—Spiro-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/08—Bridged systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/10—Spiro-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/553—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having one nitrogen atom as the only ring hetero atom
    • C07F9/572—Five-membered rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6561—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing systems of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring or ring system, with or without other non-condensed hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Reproductive Health (AREA)
  • Neurosurgery (AREA)
  • Hematology (AREA)
  • Molecular Biology (AREA)
  • Obesity (AREA)
  • Biochemistry (AREA)
  • Psychiatry (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Gynecology & Obstetrics (AREA)
  • Virology (AREA)
  • Pain & Pain Management (AREA)
  • Emergency Medicine (AREA)
  • AIDS & HIV (AREA)
  • Hospice & Palliative Care (AREA)
  • Nutrition Science (AREA)
  • Urology & Nephrology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Communicable Diseases (AREA)

Claims (20)

1. Соединение, представленное формулой I
Figure 00000001
где R1 и R2 независимо друг от друга выбраны из группы, состоящей из водорода, низшего алкила, алкенила, алкинила, галогена, нитро, циано, гидрокси, амино, низшего аминоалкила, низшего алкокси, арила, гетероарила, COOR4, CONR4R5, NHCOR4, NHSO2R4, OCOR4, COR4, SR4, S(O)nR8, SO2NR8R9;
R3 выбран из группы, состоящей из циано, нитро, S(O)nR8, SO2NR8R9, OSO2R4, P(O)(OR4)(OR5), P(O)(OH)(NR4R5), PO(NR4R5)2, COOR4;
кольцо А представляет собой 5- или 6-членный необязательно ароматический, частично насыщенный или полностью насыщенный карбоцикл или гетероцикл, содержащий до двух гетероатомов или гетерогрупп, выбранных из группы, состоящей из NR6R7, О, SO2, S, С=O и C=S;
кольцо В представляет собой необязательно замещенный моноциклический или бициклический гетероцикл, содержащий до трех гетероатомов или гетерогрупп, выбранных из группы, состоящей из NR6R7, О, SO2, S, С=O и C=S;
Y1 и Y2 представляют собой CR6R7;
R4 и R5 независимо друг от друга выбраны из группы, состоящей из водорода, циано, необязательно замещенного алкила, необязательно замещенного алкенила, необязательно замещенного алкинила, необязательно замещенного циклоалкила, необязательно замещенного гетероциклилалкила, необязательно замещенного арилалкила, необязательно замещенного арила, необязательно замещенного гетероарилалкила, необязательно замещенного гетероарила;
R6 и R7 независимо друг от друга выбраны из группы, состоящей из водорода, галогена, циано, гидрокси, необязательно замещенного алкенила, необязательно замещенного алкинила, необязательно замещенного циклоалкила, необязательно замещенного гетероциклилалкила, необязательно замещенного арилалкила, необязательно замещенного арила, необязательно замещенного гетероарилалкила, необязательно замещенного гетероарила, OR4, NR4R5, SR4, COR4, COOR4, CONR4R5, NHCOR4, OCOR4, CSR4, CSOR4, CSNR4R5, NHCSR4, OCSR4, S(O)nR4, SO2NR4R5, OSO2R4, NHSO2R4;
R8 и R9 независимо друг от друга выбраны из группы, состоящей из водорода, необязательно замещенного алкила, необязательно замещенного алкенила, необязательно замещенного алкинила, необязательно замещенного циклоалкила, необязательно замещенного гетероциклилалкила, необязательно замещенного арилалкила, необязательно замещенного гетероарилалкила; и
n означает целое число от 1 до 3;
либо их фармацевтически приемлемые соли, сложные эфиры, амиды, пролекарственные формы или стереоизомеры.
2. Соединение по п.1, в котором кольцо А представляет собой бензол, циклогексил или пиридин.
3. Соединение по п.1, в котором R3 означает циано, нитро, S(O)nR8 или SO2NR8R9.
4. Соединение по п.1, в котором R3 означает циано или нитро.
5. Соединение по п.1, в котором кольцо В необязательно замещено одной или несколькими группами, выбранными из группы, состоящей из водорода, галогена, гидрокси, необязательно замещенного алкокси, необязательно замещенного алкила, необязательно замещенного алкенила, необязательно замещенного алкинила, необязательно замещенного аминоалкила и NHCOR4.
6. Соединение по п.1, в котором кольцо В необязательно замещено одной или несколькими гидроксигруппами.
7. Соединение по п.1, в котором R6 или R7 означает гидрокси или алкил.
8. Пролекарственная форма - сложный эфир, карбонат, карбамат, сульфат, фосфат или фосфорамидат соединения по п.1.
9. Соединение, выбранное из группы, состоящей из:
4-(3-эндо-гидрокси-8-азабицикло[3.2.1]окт-8-ил)нафталин-1-карбонитрил,
4-(3-оксо-8-азабицикло[3.2.1]окт-8-ил)нафталин-1-карбонитрил,
4-{3-[2-(1Н-имидазол-4-ил)этиламино]-8-азабицикло[3.2.1]окт-8-ил}нафталин-1-карбонитрил, дигидрохлорид,
4-[3-(циклогексилметиламино)-8-азабицикло[3.2.1]окт-8-ил]нафталин-1-карбонитрил, гидрохлорид,
4-[3-(2-морфолин-4-илэтиламино)-8-азабицикло[3.2.1]окт-8-ил]нафталин-1-карбонитрил, дигидрохлорид,
метоксиуксусной кислоты эндо-8-(4-цианонафталин-1-ил)-8-азабицикло[3.2.1]окт-3-иловый эфир,
3-морфолин-4-илпропионовой кислоты эндо-8-(4-цианонафталин-1-ил)-8-азабицикло[3.2.1]окт-3-иловый эфир, гидрохлорид,
3-(4-этилпиперазин-1-ил)пропионовой кислоты эндо-8-(4-цианонафталин-1-ил)-8-азабицикло[3.2.1]окт-3-иловый эфир, гидрохлорид,
3-диэтиламинопропионовой кислоты эндо-8-(4-цианонафталин-1-ил)-8-азабицикло[3.2.1]окт-3-иловый эфир, гидрохлорид,
хлоруксусной кислоты эндо-8-(4-цианонафталин-1-ил)-8-азабицикло[3.2.1]окт-3-иловый эфир,
морфолин-4-илуксусной кислоты эндо-8-(4-цианонафталин-1-ил)-8-азабицикло[3.2.1]окт-3-иловый эфир, гидрохлорид,
имидазол-1-илуксусной кислоты эндо-8-(4-цианонафталин-1-ил)-8-азабицикло[3.2.1]окт-3-иловый эфир, гидрохлорид,
(4-этилпиперазин-1-ил)уксусной кислоты эндо-8-(4-цианонафталин-1-ил)-8-азабицикло[3.2.1]окт-3-иловый эфир, дигидрохлорид,
диэтиламиноуксусной кислоты эндо-8-(4-цианонафталин-1-ил)-8-азабицикло[3.2.1]окт-3-иловый эфир, гидрохлорид,
янтарной кислоты эндо-[8-(4-цианонафталин-1-ил)-8-азабицикло[3.2.1]окт-3-ил]овый моноэфир,
трифторуксусной кислоты эндо-8-(4-цианонафталин-1-ил)-8-азабицикло[3.2.1]окт-3-иловый эфир,
4-(эндо-3-метокси-8-азабицикло[3.2.1]окт-8-ил)нафталин-1-карбонитрил,
N-[8-(4-цианонафталин-1-ил)-8-азабицикло[3.2.1]окт-3-ил]-2-(4-этилпиперазин-1-ил)ацетамид, дигидрохлорид,
4-(3-эндо-гидрокси-3-экзо-метил-8-азабицикло[3.2.1]окт-8-ил)нафталин-1-карбонитрил,
4-(3-эндо-гидрокси-3-экзо-пропил-8-азабицикло[3.2.1]окт-8-ил)нафталин-1-карбонитрил,
4-(эндо-спиро[8-азабицикло[3.2.1]октан-3,2'-оксиран]-8-ил)нафталин-1-карбонитрил,
4-(3-экзо-цианометил-3-эндо-гидрокси-8-азабицикло [3.2.1]окт-8-ил)нафталин-1-карбонитрил,
4-нитробензойной кислоты экзо-8-(4-цианонафталин-1-ил)-8-азабицикло[3.2.1]окт-3-иловый эфир,
4-(3-экзо-гидрокси-8-азабицикло[3.2.1]окт-8-ил)нафталин-1-карбонитрил,
4-(3-экзо-метокси-8-азабицикло[3.2.1]окт-8-ил)нафталин-1-карбонитрил,
4-(8-азабицикло[3.2.1]окт-2-ен-8-ил)нафталин-1-карбонитрил,
4-(8-азабицикло[3.2.1]окт-8-ил)нафталин-1-карбонитрил,
3-пирролидин-1-илпропионовой кислоты эндо-8-(4-цианонафталин-1-ил)-8-азабицикло[3.2.1]окт-3-иловый эфир, фумарат,
3-имидазол-1-илпропионовой кислоты эндо-8-(4-цианонафталин-1-ил)-8-азабицикло[3.2.1]окт-3-иловый эфир, фумарат,
3-пиразол-1-илпропионовой кислоты эндо-8-(4-цианонафталин-1-ил)-8-азабицикло[3.2.1]окт-3-иловый эфир, фумарат,
4-(2-метил-8-азабицикло[3.2.1]окт-8-ил)нафталин-1-карбонитрил,
эндо-8-(4-цианонафталин-1-ил)-8-азабицикло[3.2.1]окт-3-ил-фосфат двукислый,
2-экзо-[8-(4-цианонафталин-1-ил)-3-эндо-гидрокси-8-азабицикло[3.2.1]окт-3-ил]-N,N-диметилэтансульфонамид,
4-(3-эндо-гидрокси-3-экзо-метил-8-азабицикло[3.2.1]окт-8-ил)нафталин-1-карбонитрил, гидрохлорид,
4-(3-метил-8-азабицикло[3.2.1]окт-2-ен-8-ил)нафталин-1-карбонитрил,
3-пиперазин-1-илпропионовой кислоты эндо-8-(4-цианонафталин-1-ил)-8-азабицикло[3.2.1]окт-3-иловый эфир, дигидрохлорид,
3-[бис(2-гидроксиэтил)амино]пропионовой кислоты эндо-8-(4-цианонафталин-1-ил)-8-азабицикло[3.2.1]окт-3-иловый эфир, фумарат,
3-(3-диметиламинопирролидин-1-ил)пропионовой кислоты эндо-8-(4-цианонафталин-1-ил)-8-азабицикло[3.2.1]окт-3-иловый эфир, дифумарат,
3-(4-метилпиперазин-1-ил)пропионовой кислоты эндо-8-(4-цианонафталин-1-ил)-8-азабицикло[3.2.1]окт-3-иловый эфир, дифумарат, и
4-(3-диэтиламинометил-3-гидрокси-8-азабицикло[3.2.1]окт-8-ил)нафталин-1-карбонитрил, гидрохлорид.
10. Соединение, выбранное из группы, состоящей из:
4-(3-эндо-гидрокси-8-азабипикло[3.2,1]окт-8-ил)нафталин-1-карбонитрил,
3-(4-этилпиперазин-1-ил)пропионовой кислоты эндо-8-(4-цианонафталин-1-ил)-8-азабицикло[3.2.1]окт-3-иловый эфир, гидрохлорид,
3-диэтиламинопропионовой кислоты эндо-8-(4-цианонафталин-1-ил)-8-азабицикло[3.2.1]окт-3-иловый эфир, гидрохлорид,
4-(3-эндо-гидрокси-3-экзо-метил-8-азабицикло[3.2.1]окт-8-ил)нафталин-1-карбонитрил,
4-(3-эндо-гидрокси-3-экзо-пропил-8-азабицикло[3.2.1]окт-8-ил)нафталин-1-карбонитрил,
4-(эндо-спиро[8-азабицикло[3.2.1]октан-3,2'-оксиран]-8-ил)нафталин-1-карбонитрил,
4-(8-азабицикло[3.2.1]окт-2-ен-8-ил)нафталин-1-карбонитрил,
4-(8-азабицикло[3.2.1]окт-8-ил)нафталин-1-карбонитрил,
4-(2-метил-8-азабицикло[3.2.1]окт-8-ил)нафталин-1-карбонитрил,
4-(3-эндо-гидрокси-3-экзо-метил-8-азабицикло[3.2.1]окт-8-ил)нафталин-1-карбонитрил, гидрохлорид, и
4-(3-метил-8-азабицикло[3.2.1]окт-2-ен-8-ил)нафталин-1-карбонитрил.
11. Соединение, выбранное из группы, состоящей из:
4-(3-пропиламино-8-азабицикло[3.2.1]окт-8-ил)нафталин-1-карбонитрил, гидрохлорид,
4-(3-диметиламино-8-азабицикло[3.2.1]окт-8-ил)нафталин-1-карбонитрил, гидрохлорид,
4-[3-(3-гидроксипропиламино-8-азабицикло[3.2.1]окт-8-ил]нафталин-1-карбонитрил, гидрохлорид,
4-[3-(2-этоксиэтиламино-8-азабицикло[3.2.1]окт-8-ил]нафталин-1-карбонитрил, гидрохлорид,
4-(3-циклопропиламино-8-азабицикло[3.2.1]окт-8-ил)нафталин-1-карбонитрил, гидрохлорид,
4-[3-(2-диметиламиноэтиламино)-8-азабицикло[3.2.1]окт-8-ил]нафталин-1-карбонитрил, дигидрохлорид,
4-{3-[(фуран-2-илметил)амино]-8-азабицикло[3.2.1]окт-8-ил}нафталин-1-карбонитрил,гидрохлорид,
4-{3-[(пиридин-2-илметил)амино]-8-азабицикло[3.2.1]окт-8-ил}нафталин-1-карбонитрил, дигидрохлорид,
4-[3-(2-изопропоксиэтиламино)-8-азабицикло[3.2.1]окт-8-ил]нафталин-1-карбонитрил, гидрохлорид,
4-(3-гидроксиимино-8-азабицикло[3.2.1]окт-8-ил)нафталин-1-карбонитрил,
3-хлорпропионовой кислоты эндо-8-(4-цианонафталин-1-ил)-8-азабицикло[3.2.1]окт-3-иловый эфир,
4-(3-экзо-этинил-3-эндо-гидрокси-8-азабицикло[3.2.1]окт-8-ил)нафталин-1-карбонитрил,
4-[3-(2-[1,3]диоксан-2-илэтил)-3-гидрокси-8-азабицикло[3.2.1]окт-8-ил] нафталин-1-карбонитрил,
4-(3-амино-8-азабицикло[3.2.1]окт-8-ил)нафталин-1-карбонитрил, гидрохлорид,
2-хлор-N-[8-(4-цианонафталин-1-ил)-8-азабицикло[3.2.1]окт-3-ил]ацетамид, гидрохлорид,
N-[8-(4-цианонафталин-1-ил)-8-азабицикло[3.2.1]окт-3-ил]-2-(4-этилпиперазин-1 -ил)ацетамид, дигидрохлорид,
2-цианоэтил-эндо-8-(4-цианонафталин-1-ил)-8-азабицикло[3.2.1]окт-3-ил-N,N-диизопропиламидофосфат,
эндо-8-(4-цианонафталин-1-ил)-8-азабицикло[3.2.1]окт-3-ил-N,N-диизопропил-амидофосфат кислый,
[8-(4-цианонафталин-1-ил)-8-азабицикло[3.2.1]окт-3-ил]мочевина,
диметилкарбаминовой кислоты эндо-8-(4-цианонафталин-1-ил)-8-азабицикло-[3.2.1]окт-3-иловый эфир,
4-[экзо-(4-этилпиперазин-1-илметил)-3-эндо-гидрокси-8-азабицикло [3.2.1]окт-8-ил]нафталин-1-карбонитрил,
4-(3-эндо-гидрокси-3-экзо-гидроксиметил-8-азабицикло[3.2.1]окт-8-ил)нафталин-1-карбонитрил,
4-(3-эндо-гидрокси-3-экзо-{[2-(1Н-имидазол-4-ил)этиламино]метил}-8-азабицикло[3.2.1]окт-8-ил)нафталин-1-карбонитрил,
4-(3-эндо-гидрокси-3-экзо-метоксиметил-8-азабицикло[3.2.1]окт-8-ил)нафталин-1-карбонитрил,
акриловой кислоты эндо-8-(4-цианонафталин-1-ил)-8-азабицикло[3.2.1]окт-3-иловый эфир,
4-(2-метил-3-оксо-8-азабицикло[3.2.1]окт-8-ил)нафталин-1-карбонитрил,
4-(3-экзо-бензил-3-эндо-гидрокси-8-азабицикло[3.2.1]окт-8-ил)нафталин-1-карбонитрил,
8-(4-цианонафталин-1-ил)-8-азабицикло[3.2.1]окт-2-ен-2-карбоновой кислоты метиловый эфир,
8-(4-цианонафталин-1-ил)-8-азабицикло[3.2.1]октан-2-карбоновой кислоты метиловый эфир,
4-(2-гидроксиметил-8-азабицикло[3.2.1]окт-2-ен-8-ил)нафталин-1-карбонитрил,
(1R,2R,3S,5S)-3-бензоилокси-8-(4-цианонафталин-1-ил)-8-азабицикло[3.2.1]октан-2-карбоновой кислоты метиловый эфир,
(1R,2R,3S,5S)-4-(3-гидрокси-2-гадроксиметил-8-азабицикло[3.2.1]окт-8-ил)-нафталин-1-карбонитрил,
2-цианоэтил-эндо-8-(4-цианонафталин-1-ил)-8-азабицикло[3.2.1]окт-3-ил-N,N-диизопропиламидофосфит,
2-цианоэтил-эндо-8-(4-цианонафталин-1-ил)-8-азабицикло[3.2.1]окт-3-ил-диизопропиламидофосфат,
2-цианоэтил-этил-эндо-8-(4-цианонафталин-1-ил)-8-азабицикло[3.2.1]окт-3-ил-фосфат,
этил-эндо-8-(4-цианонафталин-1-ил)-8-азабицикло[3.2.1]окт-3-ил-фосфат кислый,
бис(2-цианоэтил)-эндо-8-(4-цианонафталин-1-ил)-8-азабицикло[3.2.1]окт-3-ил-фосфат,
2-цианоэтил-эндо-8-(4-цианонафталин-1-ил)-8-азабицикло[3.2.1]окт-3-ил-фенилфосфат,
эндо-8-(4-цианонафталин-1-ил)-8-азабицикло[3.2.1]окт-3-ил-фенилфосфат кислый,
N-[8-(4-цианонафталин-1-ил)-8-азабицикло[3.2.1]окт-3-ил]ацетамид,
3-хлор-N-[8-(4-цианонафталин-1-ил)-8-азабицикло[3.2.1]окт-3-ил]пропанамид,
N-[8-(4-цианонафталин-1-ил)-8-азабицикло[3.2.1]окт-3-ил]-3-(4-этилпиперазин-1-ил)пропанамид, дигидрохлорид,
N-[8-(4-цианонафталин-1-ил)-8-азабицикло[3.2.1]окт-3-ил]-3-диэтиламино-пропионамид, гидрохлорид,
N-[8-(4-цианонафталин-1-ил)-8-азабицикло[3.2.1]окт-3-ил]-3-(1Н-имидазол-1-ил)пропанамид, гидрохлорид,
N-[8-(4-цианонафталин-1-ил)-8-азабицикло[3.2.1]окт-3-ил]-2-(этоксиэтокси)-ацетамид,
N'-[8-(4-цианонафталин-1-ил)-8-азабицикло[3.2.1]окт-3-ил]-4-метилбензол-сульфонилгидразон и
3-экзо-[8-(4-цианонафталин-1-ил)-3-эндо-гидрокси-8-азабицикло[3.2.1]окт-3-ил]-N,N-диметилпропанамид.
12. Способ активирования андрогеновых рецепторов, включающий контактирование данных рецепторов с соединением по п.1.
13. Способ облегчения симптомов гипогонадизма, включающий идентифицирование нуждающегося в этом пациента и введение данному пациенту соединения по п.1.
14. Способ лечения заболевания или облегчения его симптомов, включающий идентифицирование нуждающегося в этом пациента и введение данному пациенту соединения по п.1;
где заболевание выбрано из группы, состоящей из пониженного уровня тестостерона в плазме крови, бесплодия у мужчин, сперматогенеза у мужчин, расстройства эрекции у мужчин, андропаузы у мужчин, эндометриоза у женщин, диспарейнии у женщин, вагинизма у женщин, расстройства полового возбуждения у женщин, расстройства сексуального оргазма у женщин, нарушения либидо у мужчин, кахексии, истощения при ВИЧ-инфекции, критических болезней, при которых наблюдается мышечное истощение; саркопении; хрупкости; малого роста; карликовости; падения плотности костной ткани; расстройства настроения, в том числе плохого самочувствия, упадка сил, гнева, раздражительности, грусти, усталости и нервозности; депрессии; нарушений познавательной способности, в том числе беглости речи и пространственной памяти; нейродегенеративных заболеваний, в том числе болезни Альцгеймера, слабого нарушения познавательной способности (MCI), деменции тельца Льюиса и фронтотемпоральной деменции; ксерофтальмии; метаболических нарушений, в том числе дислипидемии, атеросклероза и независимого от инсулина диабета (NIDDM); сердечно-сосудистых нарушений, в том числе, но не ограничиваясь этим, гипертензии, заболеваний коронарной артерии и перфузии миокарда; ожирения; анемии; рака простаты и шизофрении.
15. Способ гормональной заместительной терапии, включающий идентифицирование нуждающегося в этом пациента и введение этому пациенту соединения по п.1.
16. Способ по п.15, в котором необходимость в гормональной заместительной терапии вызвана орхидэктомией, проведенной хирургическим или химическим способом.
17. Способ увеличения мышечной силы при заболеваниях, в том числе мышечной дистрофии, миотонической дистрофии, астме при лечении глюкокортикоидами, включающий идентифицирование нуждающегося в этом пациента и введение этому пациенту соединения по п.1.
18. Способ профилактики заболевания, выбранного из группы, состоящей из падения плотности костной ткани; ксерофтальмии; метаболических нарушений, в том числе дислипидемии, атеросклероза и независимого от инсулина диабета (NIDDM); сердечно-сосудистых нарушений, в том числе гипертензии, заболеваний коронарной артерии и перфузии миокарда; ожирения и рака простаты, включающий введение пациенту соединения по п.1.
19. Способ улучшения связанных со здоровьем параметров качества жизни, выбранных из группы, состоящей из выживаемости, ущербности, функционального статуса восприятия состояния здоровья и перспектив, включающий введение пациенту соединения по п.1.
20. Способ замедления развития рака простаты, включающий введение пациенту соединения по п.1.
RU2006144863/04A 2004-05-17 2005-05-16 Модуляторы андрогеновых рецепторов и способ лечения заболеваний с их помощью RU2006144863A (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US57196104P 2004-05-17 2004-05-17
US60/571,961 2004-05-17

Publications (1)

Publication Number Publication Date
RU2006144863A true RU2006144863A (ru) 2008-06-27

Family

ID=35241157

Family Applications (1)

Application Number Title Priority Date Filing Date
RU2006144863/04A RU2006144863A (ru) 2004-05-17 2005-05-16 Модуляторы андрогеновых рецепторов и способ лечения заболеваний с их помощью

Country Status (10)

Country Link
US (2) US7268232B2 (ru)
EP (1) EP1756101A2 (ru)
JP (1) JP2007538085A (ru)
CN (1) CN101248069A (ru)
AU (1) AU2005247405A1 (ru)
CA (1) CA2566942A1 (ru)
MX (1) MXPA06013329A (ru)
RU (1) RU2006144863A (ru)
WO (1) WO2005115361A2 (ru)
ZA (1) ZA200610270B (ru)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8420694B2 (en) 2007-08-07 2013-04-16 Takeda Pharmaceutical Company Limited Pyrrolidin-2-one derivatives as androgen receptor modulator

Families Citing this family (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004110978A2 (en) * 2003-06-10 2004-12-23 Smithkline Beecham Corporation 1-aminonaphthalenes as modulators of androgen, glucocorticoid, mineralocorticoid and progesterone receptors
CA2566942A1 (en) * 2004-05-17 2005-12-08 Acadia Pharmaceuticals Inc. Androgen receptor modulators and method of treating disease using the same
US20070004679A1 (en) * 2004-05-17 2007-01-04 Nathalie Schlienger Androgen receptor modulators and methods of treating disease using the same
AU2006205066B2 (en) 2005-01-10 2012-05-17 Acadia Pharmaceuticals Inc. Aminophenyl derivatives as selective androgen receptor modulators
US20060173037A1 (en) * 2005-01-10 2006-08-03 Nathalie Schlienger Aminophenyl derivatives as selective androgen receptor modulators
US7709516B2 (en) * 2005-06-17 2010-05-04 Endorecherche, Inc. Helix 12 directed non-steroidal antiandrogens
US20070014739A1 (en) * 2005-07-14 2007-01-18 Eldridge Gary R Compositions and methods for controlling biofilms and bacterial infections
WO2008066117A1 (fr) 2006-11-30 2008-06-05 Takeda Pharmaceutical Company Limited Composé amine cyclique
US9284345B2 (en) * 2007-04-12 2016-03-15 Endorecherche, Inc. 17alpha-substituted steroids as systemic antiandrogens and selective androgen receptor modulators
CA2709677C (en) 2007-12-21 2017-03-14 Lin Zhi Selective androgen receptor modulators (sarms) and uses thereof
US8268872B2 (en) 2008-02-22 2012-09-18 Radius Health, Inc. Selective androgen receptor modulators
MX2010009162A (es) 2008-02-22 2010-12-21 Radius Health Inc Moduladores selectivos del receptor de androgeno.
US7804063B2 (en) * 2008-10-06 2010-09-28 Quest Diagnostics Investments Incorporated Methods for detecting dihydrotestosterone by mass spectrometry
WO2010054183A2 (en) * 2008-11-07 2010-05-14 President And Fellows Of Harvard College Dyes, compositions and related methods of use
CA2788907A1 (en) 2010-02-04 2011-08-11 Radius Health, Inc. Selective androgen receptor modulators
MX342898B (es) 2010-05-12 2016-10-18 Radius Health Inc * Regimen terapéutico de la sal de diclorhidrato del (r) -6-(2-(etil (4-2(etilamino) etil) bencil) amino)-4-metoxifenil)-5, 6,7,8-tetrahidronaftaleno-2-ol.
US8642632B2 (en) 2010-07-02 2014-02-04 Radius Health, Inc. Selective androgen receptor modulators
ES2550319T3 (es) 2010-09-28 2015-11-06 Radius Health, Inc Moduladores selectivos del receptor de andrógenos
US9175291B2 (en) 2012-10-11 2015-11-03 Isis Pharmaceuticals Inc. Modulation of androgen receptor expression
DK2925725T3 (en) * 2012-12-03 2017-01-16 Pfizer androgen receptor modulators
CN106414432B (zh) 2013-10-14 2019-06-14 卫材R&D管理有限公司 选择性取代的喹啉化合物
RU2671496C2 (ru) 2013-10-14 2018-11-01 Эйсай Ар Энд Ди Менеджмент Ко., Лтд. Производные 5-пиперидин-8-цианохинолина
US9682960B2 (en) 2013-12-19 2017-06-20 Endorecherche, Inc. Non-steroidal antiandrogens and selective androgen receptor modulators with a pyridyl moiety
EP3613418A1 (en) 2014-01-17 2020-02-26 Ligand Pharmaceuticals, Inc. Methods and compositions for modulating hormone levels
US10328082B2 (en) * 2014-05-30 2019-06-25 Pfizer Inc. Methods of use and combinations
RU2604681C1 (ru) * 2015-06-29 2016-12-10 Государственное бюджетное образовательное учреждение высшего профессионального образования "Ивановская государственная медицинская академия" Министерства здравоохранения Российской Федерации Способ прогнозирования эффективности лечения хорионическим гонадотропином у мужчин с гипогонадизмом
WO2017034997A1 (en) 2015-08-21 2017-03-02 Portola Pharmaceuticals, Inc. Phenylpiperazine proprotein convertase subtilisin/kexin type 9 (pcsk9) modulators and their use
WO2017034994A1 (en) 2015-08-21 2017-03-02 Portola Pharmaceuticals, Inc. Composition and methods of use of novel phenylalanine small organic compounds to directly modulate pcsk9 protein activity
US10865185B2 (en) 2015-08-21 2020-12-15 Srx Cardio, Llc Composition and methods of use of tetrahydroisoquinoline small molecules to bind and modulate PCSK9 protein activity
DK3889145T3 (da) 2015-12-17 2024-03-18 Merck Patent Gmbh 8-cyano-5-piperidino-quinoliner som TLR7/8-antagonister og anvendelser deraf til behandling af immunsygdomme
WO2017147328A1 (en) 2016-02-23 2017-08-31 Portola Pharmaceuticals, Inc. Compounds for binding proprotein convertase subtilisin/kexin type 9 (pcsk9)
LT3474841T (lt) 2016-06-22 2022-06-10 Ellipses Pharma Ltd Ar+ krūties vėžio gydymo būdai
BR112019000696A2 (pt) 2016-08-08 2019-04-24 Merck Patent Gmbh antagonistas de tlr7/8 e uso dos mesmos
EP4248968A3 (en) * 2017-07-18 2023-12-06 Merck Patent GmbH Tlr7/8 antagonists and uses thereof
EP3844159B1 (en) * 2018-08-28 2023-05-03 F. Hoffmann-La Roche AG Novel pyrrolidinyl amide compounds for the treatment of autoimmune disease
MX2021013774A (es) 2019-05-14 2021-12-10 Nuvation Bio Inc Compuestos anticancerigenos dirigidos a los receptores hormonales nucleares.
US11952349B2 (en) 2019-11-13 2024-04-09 Nuvation Bio Inc. Anti-cancer nuclear hormone receptor-targeting compounds
US12115154B2 (en) 2020-12-16 2024-10-15 Srx Cardio, Llc Compounds for the modulation of proprotein convertase subtilisin/kexin type 9 (PCSK9)
US11834458B2 (en) 2021-03-23 2023-12-05 Nuvation Bio Inc. Anti-cancer nuclear hormone receptor-targeting compounds
JP2024516024A (ja) 2021-05-03 2024-04-11 ニューベイション・バイオ・インコーポレイテッド 抗がん核内ホルモン受容体標的化化合物

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL140992B (nl) * 1963-07-06 1974-01-15 Kalle Ag Kopieermateriaal, dat een lichtgevoelig diazoniumzout bevat en werkwijze voor het bereiden van dat zout.
US4933447A (en) * 1987-09-24 1990-06-12 Ss Pharmaceutical Co., Ltd. Quinoline derivatives
JPH01156960A (ja) * 1987-09-24 1989-06-20 Ss Pharmaceut Co Ltd キノリン誘導体
IL110298A (en) * 1993-07-13 1999-04-11 Brann Mark Robert Identification of ligands by selective amplification of cells transfected with receptors
ES2193201T3 (es) * 1994-11-15 2003-11-01 Upjohn Co Agentes antibacterianos tipo oxazolidonas sustituidas con oxazina y tiazina biciclica.
AT403803B (de) * 1996-04-19 1998-05-25 Sanochemia Ltd Neue benzazepinderivate, diese enthaltende arzneimittel und verwendung derselben zum herstellen von arzneimitteln
TR200003595T2 (tr) * 1998-06-05 2001-07-23 Astrazeneca Ab Kimyasal bileşikler
ES2300151T3 (es) * 1998-09-22 2008-06-01 Astellas Pharma Inc. Derivados de cianofenilo.
DE10134785A1 (de) 2001-07-17 2003-02-06 Diehl Munitionssysteme Gmbh Verfahren zur Flugbahnkorrektur ballistisch verschossener drallstabilisierter Artilleriemunition
EP1414795A4 (en) 2001-07-31 2006-03-01 Bristol Myers Squibb Co BICYCLIC MODULATORS OF THE FUNCTION OF THE ANDROGEN RECEPTOR
TW200407324A (en) * 2002-05-17 2004-05-16 Bristol Myers Squibb Co Bicyclic modulators of androgen receptor function
US7405234B2 (en) * 2002-05-17 2008-07-29 Bristol-Myers Squibb Company Bicyclic modulators of androgen receptor function
KR20050044902A (ko) * 2002-08-12 2005-05-13 다케다 야쿠힌 고교 가부시키가이샤 축합 벤젠 유도체 및 용도
US6933311B2 (en) * 2003-02-11 2005-08-23 Abbott Laboratories Fused azabicyclic compounds that inhibit vanilloid receptor subtype 1 (VR1) receptor
US20050113576A1 (en) * 2003-08-05 2005-05-26 Chih-Hung Lee Fused azabicyclic compounds that inhibit vanilloid receptor subtype 1 (VR1) receptor
WO2005090282A1 (en) * 2004-03-12 2005-09-29 Ligand Pharmaceuticals Incorporated Androgen receptor modulator compounds and methods
CA2566942A1 (en) * 2004-05-17 2005-12-08 Acadia Pharmaceuticals Inc. Androgen receptor modulators and method of treating disease using the same

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8420694B2 (en) 2007-08-07 2013-04-16 Takeda Pharmaceutical Company Limited Pyrrolidin-2-one derivatives as androgen receptor modulator

Also Published As

Publication number Publication date
US20080009489A1 (en) 2008-01-10
WO2005115361A2 (en) 2005-12-08
WO2005115361A3 (en) 2006-03-16
CN101248069A (zh) 2008-08-20
CA2566942A1 (en) 2005-12-08
US7268232B2 (en) 2007-09-11
AU2005247405A1 (en) 2005-12-08
MXPA06013329A (es) 2007-02-22
ZA200610270B (en) 2008-06-25
EP1756101A2 (en) 2007-02-28
JP2007538085A (ja) 2007-12-27
US20060014739A1 (en) 2006-01-19

Similar Documents

Publication Publication Date Title
RU2006144863A (ru) Модуляторы андрогеновых рецепторов и способ лечения заболеваний с их помощью
JP2007538085A5 (ru)
JP5694765B2 (ja) グルタミン酸作動性シナプス反応を増強するための二置換アミド
JP7355741B2 (ja) ベンズアミド化合物
RU2007130558A (ru) Производные аминофенола в качестве селективных модуляторов андрогеновых рецепторов
JP5257073B2 (ja) ソフト型抗コリン作動性エステル
JP2008526888A5 (ru)
EA030698B1 (ru) Ингибиторы деметилаз гистонов
JP2016026165A (ja) 新規アミドおよびアミジン誘導体ならびにこれらの使用
JP2010526129A5 (ru)
JP5576277B2 (ja) グルタミン酸作動性シナプス反応を増大するための二環式アミド
HU905216D0 (en) Process for the production of heterocyclic amines and medical preparations containing them, which effect the central nerve-system
EA035768B1 (ru) Способ получения соединения, содержащего индановую группу с хиральным атомом углерода в пятичленном кольце индановой группы
EA007590B1 (ru) Производные тропана в качестве модуляторов ccr5
JP2009514818A (ja) 置換アミドの製薬学的用途
JP2013510883A5 (ru)
EA009941B1 (ru) Имидазопиридинзамещённые тропановые производные, обладающие активностью антагониста ccr5 рецептора, для лечения вируса иммунодефицита человека (вич) и воспаления
JP2010527984A5 (ru)
JP7071342B6 (ja) 改善されたバイオアベイラビリティを有するジアリールプリン誘導体
JP2007523865A (ja) 疼痛治療に有用な新規なアザ複素環アミド類
JP2022501366A (ja) イソオキサゾールカルボキサミド化合物及びその使用
JPWO2015182724A1 (ja) 置換トロパン誘導体
WO2024211360A2 (en) Specific reversal agents to treat acute and chronic toxicity of fentanyls
AU2013205446A1 (en) Bicyclic amides for enhancing glutamatergic synaptic responses
EA018994B1 (ru) Производные бициклического амида для усиления глутаматергических синаптических ответов

Legal Events

Date Code Title Description
FA92 Acknowledgement of application withdrawn (lack of supplementary materials submitted)

Effective date: 20100125